Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
25.59
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Deciphera Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RBAZ Bancorp, Inc. (OTCPK - RBAZ), Squarespace, Inc. (NYSE - SQSP), PlayAGS, Incorporated (NYSE - AGS), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH)
June 18, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
June 03, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RBAZ Bancorp, Inc. (OTCPK - RBAZ), Squarespace, Inc. (NYSE - SQSP), PlayAGS, Incorporated (NYSE - AGS), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH)
May 30, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RBAZ Bancorp, Inc. (OTCPK - RBAZ), Squarespace, Inc. (NYSE - SQSP), PlayAGS, Incorporated (NYSE - AGS), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH)
May 20, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Squarespace, Inc. (NYSE – SQSP), PlayAGS, Incorporated (NYSE – AGS), HashiCorp Inc. (Nasdaq – HCP), Deciphera Pharmaceuticals, Inc. (Nasdaq – DCPH)
May 13, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: PlayAGS, Incorporated (NYSE - AGS), HashiCorp Inc. (Nasdaq - HCP), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH), Territorial Bancorp, Inc. (Nasdaq - TBNK)
May 09, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH
May 01, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HashiCorp Inc. (Nasdaq - HCP), Heartland Financial, USA Inc. (Nasdaq - HTLF), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH), Territorial Bancorp, Inc. (Nasdaq -
April 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders
April 29, 2024
From
Halper Sadeh LLC
Via
Business Wire
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
April 29, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 09, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
February 27, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
February 06, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
February 01, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
January 18, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
January 08, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
January 05, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
November 29, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
November 07, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
October 30, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
October 30, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
August 09, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
August 03, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
August 02, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
May 25, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
May 23, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.